Posts by: Alejandra Viviescas, PhD

Alejandra Viviescas, PhD

Alejandra has a PhD in Genetics from São Paulo State University (UNESP) and is currently working as a scientific writer, editor, and translator. As a writer for BioNews, she is fulfilling her passion for making scientific data easily available and understandable to the general public. Aside from her work with BioNews, she also works as a language editor for non-English speaking authors and is an author of science books for kids.

May 29, 2019May 29, 2019

First Prognostic Test for IBD Now Available for Patients in the UK and Ireland

News

PredictImmune‘s prognostic test for inflammatory bowel disease (IBD) is now available to clinicians and gastroenterologists in the U.K. and Ireland, the company announced. Developed in partnership with the University of ... Read more

March 4, 2019March 4, 2019

Gene Mutations May Predict Risk of IBD Treatments’ Side Effects

News

Mutations in the NUDT15 gene may predict predisposition to side effects of immunosuppressants — substances that change the function of the immune system — in European patients with inflammatory bowel disease (IBD), ... Read more

February 25, 2019February 25, 2019

Humira Safe and Effective for up to Six Years in Crohn’s Disease Patients, Study Shows

News

Humira (adalimumab) is safe and effective for Crohn’s disease (CD) patients for up to six years when used in routine clinical practice, a study suggests. The study, “Adalimumab Effectiveness Up ... Read more

February 22, 2019February 22, 2019

FDA Accepts Koutif Therapeutics’ Investigational New Drug Application for KT-1002

News

The U.S. Food and Drug Administration (FDA) has accepted Koutif Therapeutics’ investigational new drug (IND) application for KT-1002. The company is set to begin a Phase 1 clinical trial testing the experimental therapy in inflammatory ... Read more

February 8, 2019February 8, 2019

Diet Rich in Fish-derived Fats Might Cut IBD Risk, Review Study Suggests

News

A diet rich in fish, especially those containing high amounts of long-chain polyunsaturated fatty acids (PUFAs), might reduce the risk of inflammatory bowel disease, a review study suggests. But further studies are ... Read more

January 23, 2019January 23, 2019

Gut Microbe-Derived Molecule UroA and Its Artificial Version Show Promise for IBD

News

Urolithin A (UroA), a molecule produced by gut microbes, and its made-in-the-lab version, UAS03, alleviated and prevented symptoms of inflammatory bowel disease (IBD) in a cell and animal study. ... Read more

January 16, 2019January 16, 2019

Oral Treatment Candidate Etrasimod Found to be Safe and Effective for Ulcerative Colitis, Open-label Trial Extension Shows

News

Arena Pharmaceuticals announced that its investigational oral treatment, Etrasimod, led to long-term clinical response and remission in patients with ulcerative colitis. The candidate treatment was also found to be safe ... Read more

January 4, 2019January 4, 2019

Abivax to Present Results of Trials of ABX464 as Ulcerative Colitis Therapy

News

Abivax will present the complete results of its Phase 2a trial ABX464-101 (NCT03093259) and interim results of the open-label extension study ABX464-102 (NCT03368118). Both aimed to assess the safety and efficacy of ABX464 as a ... Read more

December 14, 2018December 14, 2018

Janssen Launching Phase 1 Trial Testing VE202 for Potential IBD Treatment

News

Janssen Biotech will conduct a Phase 1 clinical trial in healthy volunteers to test VE202, an investigational oral treatment for inflammatory bowel disease (IBD), Vedanta Biosciences has announced. In 2015, Janssen ... Read more